HQL
abrdn Life Sciences Investors
NYSE · Financial Services · Asset Management · US
$17.03
+1.49%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- 5.75x
- PEG TTM
- —
- Price / book
- 0.88x
- Price / sales
- 5.69x
- Price / cash flow
- -211.91x
Enterprise value
- Enterprise value
- $490.8M
- EV / sales
- 5.68x
- EV / EBITDA
- 5.73x
- EV / EBIT
- 5.73x
- Market cap
- $491.7M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Mar 1, 2026